Onxeo receives $25M milestone payment from Spectrum on Beleodaq

14 November 2014

Onxeo (Euronext Paris: ONXEO), created by a merger between French company BioAlliance Pharma, and Danish biopharmaceutical company Topotarget, confirmed receipt of $25 million related to the approval of Beleodaq (belinostat) by the US Food and Drug Administration from its US partner Spectrum Pharmaceuticals (Nasdaq: SPPI).

Early July 2014, Beleodaq was granted conditional marketing authorization for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) under the FDA's accelerated approval program (The Pharma Letter July 4). Related to that, Onxeo US partner Spectrum Pharmaceuticals has paid the $25 million milestone as planned by contract.

Beleodaq already generating sales

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology